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600Peripheral Blood Lymphocyte and Monocyte Recovery
and Survival in Acute Leukemia Postmyeloablative
Allogeneic Hematopoietic Stem Cell Transplant
Mary D. Thoma, Tanya J. Huneke, Lori J. DeCook, Nicci D. Johnson, Rob A. Wiegand,
Mark R. Litzow, William J. Hogan, Luis F. Porrata, Shernan G. HoltanMany previous studies of immune reconstitution (IR) postallogeneic hematopoietic stem cell transplantation
(HSCT) have focused on lymphocyte recovery. Recognizing that IR involves complex interactions between
innate and adaptive immune networks, we hypothesized that patterns of both monocyte and lymphocyte re-
covery could provide additional prognostic information. To test our hypothesis, we analyzed data from
135 consecutive patients undergoing myeloablative allogeneic HSCT for acute myeloid (AML) and lympho-
blastic leukemia (ALL) from 2001 to 2010. The absolute lymphocyte and monocyte counts (ALC and AMC,
respectively) were determined longitudinally at days115,130,160, and1100, and correlated with clinical
outcomes. At the day130 time point, both ALC and AMC.0.3 109 cells/L were strongly associated with
improved survival (overall survival [OS] 29.6 months versus 5.4 months, P5.006 and 25.3 months versus 5.1
months, P5 .01 respectively), a pattern that generally continued through the day1100 evaluation. Multivar-
iate analysis revealed the following independent prognostic factors: early disease status at transplantation,
the development of chronic GVHD, the day130 AMC, day1100 AMC, and day1100 ALC. To further ex-
plore whether any inherent patterns in the timing of lymphocyte and monocyte recovery had prognostic
value post-HSCT, we performed unsupervised hierarchical clustering on the longitudinal hematopoietic pa-
rameters studied in this cohort. Four clusters of patients were identified: clusters A-D. Patient clusters B and
D both demonstrated improved ALC and AMC recovery at the day160 and day1100 time points and had
significantly improvedOS compared with clusters A and C (57.8 months versus 19.7 and 4.4 months, respec-
tively, P\.001). Our data suggest that patients with poor lymphocyte andmonocyte recovery beyond the day
160 time points may be at risk for poorer outcomes, and that further investigation into lymphoid/
myeloid interactions in developing individualized immunotherapy is warranted.
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reconstitutionINTRODUCTION
A growing body of literature supports the premise
of rapid lymphocyte recovery as paramount for long-
term survival postallogeneic hematopoietic stem cell
transplantation (HSCT) for acute leukemia [1-9].
Similarly, an improvement in survival attributed to
rapid lymphocyte recovery in the setting of systemic
chemotherapy and autologous transplantation forDivision of Hematology, Department of Medicine, Mayo
Graduate School of Medicine, Rochester, Minnesota.
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6/j.bbmt.2011.08.007hematologic malignancies has been described,
suggesting thismay be a near-universal surrogate for im-
proved clinical outcomes in cancer therapy [10]. In con-
trast to diverse, memory-capable lymphocytes that give
rise to the adaptive immune system, cells of the mono-
cytic lineage are a key component of innate immunity,
important for restoration of tissue integrity at sites of in-
jury and control of inflammatory responses [11]. Increas-
ing evidence of lymphocyte effector function being
orchestrated at least in part by themyeloid compartment
exists [12,13], and the possible implications of this
phenomenon postallogeneic HSCT has not previously
been evaluated in the clinical setting. We therefore
sought to determine whether patterns of peripheral
blood lymphocyte and monocyte recovery as assessed
by routine laboratory monitoring with complete blood
counts in the period postallogeneic HSCT through day
1100 could further identify patients at risk of impaired
IR and poor long-term survival.
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Patient Characteristics
Patients in this cohort underwent a myeloablative
allogeneic HSCT as a part of therapy for acute mye-
logenous leukemia (AML) or acute lymphoblastic leu-
kemia (ALL). From 2001 to 2010, 135 consecutive
AML and ALL patients were identified for the study,
and all were included for analysis. All patients gave
written consent to use their medical records for
research. No patients were lost to follow-up. Approval
for the retrospective review of these records was ob-
tained from theMayo Clinic institutional review board
and was in accordance with U.S. federal regulations
and the Declaration of Helsinki.End Points
The primary end point of the study was to assess
the role of peripheral blood lymphocyte and monocyte
recovery at days 115, 130, 160, and 1100 post-
HSCT on overall survival (OS). The absolute lympho-
cyte (ALC) andmonocyte counts (AMC)were obtained
by the complete blood cell count [14] at days115,130,
160, and 1100 post-HSCT.Prognostic Factors and Survival
The prognostic factors evaluated in the study in-
cluded: age at transplantation, disease status at trans-
plantation, stem cell source from a related versus an
unrelated donor, CD341 cell dose, presence/grade of
acute graft-versus-hose disease (aGVHD) based upon
the Glucksberg-Seattle grading system [15], and ALC
and AMC recovery post-HSCT. Relapse-free survival
(RFS) was defined as the time from transplantation to
documented relapse of the underlying malignancy.
OS was defined from the time of transplantation to
last follow-up or death due to any cause.Statistical Analysis
OS estimates were determined using the approach
of Kaplan andMeier [16]. Differences between survival
curves were tested for statistical significance using the
2-tailed log-rank test. The Cox proportional hazard
model was used for univariate andmultivariate analysis
to evaluate variables. For determination of appropriate
cutoffs for survival analyses, an ALC cutoff of 0.2 109
cells/L showed the greatest survival difference
(c2 5 34.2), but relatively few patients had such a low
number at the later time points (6 patients at day
1100). Therefore, 0.3  109 cells/L was selected for
ALC cutoff (c2 5 18.4 at day 1100, 12 patients
below the cutoff), a more stringent value, which is still
within the lymphopenic range. AnAMCcutoff of 0.3
109 cells/L demonstrated greatest difference in survival
by log-rank tests (c2 5 17.0 at day 1100, 21 patientsbelow the cutoff) and was therefore used as the cutoff
for survival analysis. Associations between categoric
variables were determined by the Fisher exact test.
Correlations between continuous variables in were de-
termined by Spearman’s rho. Because of multiple com-
parisons with this analysis, a Bonferroni correction was
applied. Unsupervised hierarchical clustering was per-
formed according to Ward’s method. All P values rep-
resented were 2 sided, and statistical significance was
declared at P\ .05.RESULTS
Patient Characteristics
Patient characteristics are described in Table 1.
Themedian age of the cohort was 43 years with a slight
female predominance (54.8%). The underlying disease
was AML in 67.4%, and most received high-dose
cyclophosphamide and total body irradiation as the
conditioning regimen (89.6%). All patients received
consistent supportive care including calcineurin
inhibitor-based graft-versus-host disease prophylaxis.
The majority of the stem cell grafts were derived
from fully matched related donors. Approximately
one-half of patients underwent allogeneic HSCT in
their first remission. Median OS for the entire cohort
was 24.5 months with an estimated 45% exhibiting
long-term survival (beyond 5 years) by Kaplan-Meier
estimates. A total of 65 patients have died at the time
of analysis with a median follow-up of 26.7 months
for the living. A total of 34 patients (25%) in this
cohort died from nonrelapse complications, and 31
patients (23%) died from relapsed leukemia.
Graft Source and ALC and AMC Recovery
Grafts derived from peripheral blood (PB) have
previously shown superiority in lymphocyte recovery
compared with bone marrow (BM)-derived grafts [1].
Because 24 patients in this cohort received BM-
derived grafts, we sought to determine differences in
ALC and AMC recovery between these groups. PB
grafts demonstrated significantly improved initial
ALC and AMC recovery over BM-derived grafts. At
day 115, recipients of PB grafts had achieved the
defined cutoff of both ALC (P 5 .002) and AMC
(P \ .001). At day 130, ALC (P 5 .003) but not
AMC recovery (P 5 1.0) was superior in PB-derived
grafts. At both day 160 and day 1100, there was no
difference in ALC or AMC recovery between PB- or
BM-derived grafts (not shown).
ALC and AMC Recovery, RFS, and OS:
Univariate Analysis
Achievement of ALC .0.3  109 cells/L at day
130 was associated with improved RFS (P 5 .01). A
trend toward improved RFS was noted with
Table 1. Patient Characteristics and Univariate Overall
Survival Analysis
Characteristic Patients (N 5 135) % P
Year of transplant,
median (range)
2006 (2001-2010) .037
Age, median (range) 43 (18-62) .37
Sex
Male 61 45.2% .44
Female 74 54.8%
Disease
AML 91 67.4% .1
ALL 44 32.6%
Conditioning
Cy/TBI 121 89.6% .44
Bu/CY 12 8.9%
VP16/TBI 2 1.5%
Donor type
Related 112 83.0% .14
Unrelated 23 17.0%
Stem cell source
Peripheral blood 111 82.2% .45
Marrow 24 17.8%
Match degree
Complete match 116 85.9% .76
1 antigen mismatch 15 11.1%
2 antigen mismatch 4 3.0%
Disease status at transplant
CR1 63 46.7% <.001
CR2+ 31 23.0%
Relapse/resistant 40 29.6%
Treatment-naive 1 0.7%
Number of CD34+
cells  106/kg
infused, median (range)
6.18 (2.25-12.14) .13
Days to ANC 500,
median (range)
16 (7-34) .06
Days to platelet 50,000
median (range)
19 (0-393) .91
Grade of aGVHD
0 53 39.3% .012
1 25 18.5%
2 29 21.5%
3 16 11.9%
4 6 4.4%
CMV reactivation
Yes 39 28.9% .11
No 96 71.1%
Development of cGVHD
Yes 71 52.6% <.001
No 64 47.4%
Received DLI infusion
Yes 14 10.4%
No 121 89.6%
Relapse
Yes 31 23.0%
No 104 77.0%
Cause of death
Relapse-related 31 23.0%
Nonrelapse related 34 25.2%
ALC 15 > 0.3  10(9)/L 0 0.0% .31
AMC 15 > 0.3  10(9)/L 64 47.4% .85
ALC 30 > 0.3  10(9)/L 23 17.0% .02
AMC 30 > 0.3  10(9)/L 8 5.9% .01
ALC 60 > 0.3  10(9)/L 15 11.1% .35
AMC 60 > 0.3  10(9)/L 33 24.4% .004
ALC 100 > 0.3  10(9)/L 12 8.9% <.001
AMC 100 >0.3  10(9)/L 21 15.6% <.001
ANC indicates absolute neutrophil count; Bu, busulfan; CR, complete
remission; Cy, cyclophosphamide; DLI, donor-leukocyte infusion; TBI,
total body irradiation.
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and day 1100 (P 5 .08 and .07, respectively). Very
early ALC and AMC recovery at the day 115 time
point was not associated with improved OS
(Figure 1). However, by the day 130 time point,
both ALC and AMC.0.3  109 cells/L were strongly
associated with improved OS (29.6 months versus 5.4
months, P5 .006 and 25.3 months versus 5.1 months,
P 5 .01, respectively). This pattern of improved OS
with improved counts continued through the day
1100 evaluation, with the exception of the day 160
ALC, where a statistically significant difference in sur-
vival based upon the cutoff chosen was not apparent.
The measured hematologic parameters did not have
an apparent influence on survival when analyzed as
continuous variables (data not shown). Other variables
associated with OS included the year of transplanta-
tion, disease status at transplantation, grade of
aGVHD, and the development of chronic GVHD
(cGVHD) (Table 1). Related versus unrelated donors,
peripheral blood versus marrow stem cell source,
number of stem cells infused, and cytomegalovirus
(CMV) reactivation did not appear to impact survival.
ALC and AMC Recovery and OS: Multivariate
Analysis
Multivariate analysis (Table 2) including the
parameters that demonstrated a significant difference
in OS in the univariate analysis revealed the following
independent prognostic factors: disease status at
transplantation, development of cGVHD, day 130
AMC, day 1100 ALC, and day 1100 AMC.
Associations with ALC and AMC Recovery
We assessed correlations between ALC and AMC
recovery as continuous variables with time to neutro-
phil and platelet engraftment, CD341 cell dose,
CMV reactivation, and aGVHD and cGVHD. Statis-
tically significant correlations of at least moderate
intensity are listed in Table 3. Day 115 ALC and
AMC are strongly and positively correlated with each
other and negatively correlated with the number of
days to neutrophil and platelet engraftment, suggesting
these values are associated with initial engraftment in
general. CMV reactivation is negatively associated
with day 160 AMC, which may reflect treatment
with a potentially myelosuppressive antiviral agent at
that time point. Even though independent in the
multivariate survival analysis, the day 1100 ALC
andAMC show amoderate positive association (Spear-
man’s r 5 0.4). Patients who achieved a day 1100
ALC .0.3  109 cells/L were likely to also achieve
a day 1100 AMC .0.3  109 cells/L (90 patients,
P 5 .001). We determined no significant difference
in nonrelapse mortality (NRM), relapse-related
mortality, or cGVHD severity in patients in whom
Figure 1. Kaplan-Meier estimates of overall survival (OS) by absolute lymphocyte count (ALC) and absolutemonocyte count (AMC) at days115,130,
160, and 1100.
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selected time points (not shown). Two patients re-
ceived a donor-leukocyte infusion before day 1100 (1
at day141, and the other at day196) and their results
did not significantly skew the ALC data (not shown).Table 3. Associated Variables
By Spearman’s BonferroniPatterns of ALC and AMC Recovery and
Survival
To determine whether any inherent patterns in
the timing of ALC or AMC recovery within the first
100 days posttransplantation could impact survival,
we performed unsupervised hierarchical clustering
(Figure 2) on the longitudinal hematopoietic parame-
ters studied in this cohort.Using thismethod, 4 clusters
of patients could be identified: clusters A to D. Cluster
A patients were generally characterized by low ALCTable 2. Multivariate Overall Survival Analysis
Variable Risk Ratio 95% CI P
Year of transplantation 0.80 0.19-3.49 .76
Grade of aGVHD 1.27 0.99-1.64 .06
Development of cGVHD 0.32 0.16-0.64 .0012
Disease status at transplantation 0.24 0.11-0.54 .006
ALC 30 >0.3  109/L 0.65 0.25-1.52 .33
AMC 30 >0.3  109/L 0.10 0.03-0.47 .0065
AMC 60 >0.3  109/L 0.69 0.035-1.38 .29
ALC 100 >0.3  109/L 0.22 0.09-0.59 .0032
AMC 100 >0.3  109/L 0.41 0.20-0.91 .03
CI indicates confidence interval.
Bold data indicates statistical significance with P < 0.05.and AMC early posttransplantation along with severe
lymphopenia being near-universal at day160. Cluster
B patients had a low ALC and AMC at day 115 but
generally had counts above the cutoff at the rest of
the measured time points. Cluster C patients had
good early count recovery, but a majority had a low
AMC and ALC at day 1100. Cluster D patients, with
the exception of a few, generally had ALC and AMC
levels above the cutoff for all time pointsmeasured. Im-
portantly, patient clusters B andDhad significantly im-
proved OS compared with clusters A and C (median
survival not reached for clusters B and D versus 21.3
and 4.6 months, respectively, P \ .001, Figure 3).
This survival difference between the patient clustersVariable Variable Rho P P
D15AMC D15ALC 0.74 1.31E-24 <.0001
D30ALC D15ALC 0.47 9.01E-09 <.0001
D100ALC D60ALC 0.44 6.81E-07 .0001
Days to ANC 500 Days to Plt 50 0.41 2.88E-05 .004
D100AMC D100ALC 0.40 7.16E-06 .001
D60ALC D30ALC 0.40 3.63E-06 .0005
D30AMC D30ALC 0.30 3.85E-04 .05
Days to ANC 500 D30ALC 20.35 1.24E-04 .02
Days to Plt 50 D15AMC 20.44 8.26E-06 .001
CMV reactivation D60AMC 20.47 4.10E-08 <.0001
Days to Plt 50 D15ALC 20.50 1.38E-07 <.0001
Days to ANC 500 D15ALC 20.67 1.65E-16 <.0001
Days to ANC 500 D15AMC 20.68 3.73E-17 <.0001
ANC indicates absolute neutrophil count.
Figure 2. Unsupervised hierarchical clustering of dichotomized absolute
lymphocyte count (ALC) and absolute monocyte count (AMC) at days
115,130,160, and1100. Each row is a unique patient, and each column
is a unique hematologic parameter. The bars on the left depict overall
survival (OS), with those patients with longer bars exhibiting longer OS.
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ALC and AMC recovery at the day160 and day1100
time points, which is consistent with the result of the
multivariate analysis demonstrating count recovery
by day 1100 being more prognostically important
than very early ALC and AMC recovery. We did not
identify any particular patterns of lymphocyte and
monocyte recovery within the first 100 days posttrans-
plantation that was clearly associated with relapse of
the underlying malignancy, which occurred in 31
patients (22.9%) in this cohort.
Relapse-Related Mortality and NRM in Patient
Clusters
There was no significant difference between the
patient clusters in terms of rates of relapse (not shown).Figure 3. Kaplan-Meier estimate of overall survival (OS) by patient
cluster as identified by unsupervised hierarchical clustering. Nineteen
patients experienced early deaths and therefore could not be clustered.Although there was no statistically significant differ-
ence overall between the severity of acute GVHD
between clusters (overall P 5 .10). Clusters B and D,
the 2 clusters showing the best OS, were the only
patient clusters to not have any patients experiencing
grade 4 GVHD. When considering NRM as a whole
(of which GVHD is a component), clusters B and
D demonstrated significantly lower rates of NRM
compared with the other clusters, accounting for 6 of
the 34 NRM-related deaths overall (P5 .01).
Clinical and Hematopoietic Factors in the ‘‘No
Cluster’’ Group
A total of 19 patients did not fall into a cluster
primarily because they died before day 1100. There
was no significant difference in this group who experi-
enced early deaths versus those patients who were able
to be clustered based on the following factors: periph-
eral blood or marrow graft source (P5 .74), related or
unrelated stem cell source (P 5 .87), sex of the recipi-
ent (P5 .62), AML versus ALL (P5 1.00), CD341 cell
dose (P 5 .97), grade of aGVHD (P 5 .45), age at
HSCT (P 5 .34), days to absolute neutrophil count
(ANC) 500 (P 5 .45), days to platelet count of
50,000 (P 5 .74), day 115 ALC (P 5 .80), day 115
AMC (.61), day 130 AMC (P 5 .29). However, there
was a trend toward fewer patients in the ‘‘No cluster’’
group achieving a day 130 ALC of 0.3  109/L (P 5
.07), and by day 160, those in the ‘‘No cluster’’ group
had statistically significantly inferior ALC recovery
(P5 .02) than those patients who were able to be clus-
tered. NRM was the major contributor to mortality in
the ‘‘No cluster’’ group, accounting for 76.5% of the
deaths (P 5 .02). Although not statistically significant
(P 5 .23), the ‘‘No cluster’’ group had 11 (57.9%)
entering the transplantation with active leukemia,
compared with 13.5% to 33.3% observed in the other
groups, which potentially also contributed to the
poorer outcomes we observed.DISCUSSION
In this study, we demonstrate an independent prog-
nostic benefit to monocyte recovery, in addition to
established prognostic factors postmyeloablative alloge-
neic HSCT for acute leukemia: disease status at trans-
plant, the development of cGVHD, and lymphocyte
recovery. In this cohort, achievement of a normalmono-
cyte count and a lymphocyte count.0.3 109 cells/Lby
day1100 had a substantial impact on the success of the
transplant. It is possible that the course early posttrans-
plantation can be very heterogenous in terms of initial
toxicities (tissue damage from conditioning, infections
and their treatment, and the development of GVHD)
that significantly impact hematopoiesis. With appropri-
ate supportive care, recovery from those early toxicities is
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monocyte reconstitution. Although the pattern of ALC
and AMC recovery resulting in improved survival is ap-
parent by day 130, recovery of ALC and AMC by the
day 1100 time point appears to be more significant for
long-term survival. Some caveats must be considered
when interpreting this data. At this time, the results of
our analysis cannot be generalized to reduced-intensity
conditioning allogeneic HSCT. A similar analysis
of ALC and AMC recovery in a reduced-intensity
conditioning cohort from our institution is ongoing.
Additionally, although our findings are supportive of ad-
ditional investigation into therapies to enhance activity
within the monocyte compartment as a component of
early, individualized immunologic supportive care
postallogeneic HSCT, the possibility remains that our
observations may be secondary phenomena, and that
we have yet to identify the primary cause of inferior out-
comes in patients with poor ALC and AMC recovery.
Lymphocyte recovery has beenwell documented to
be important for survival in this setting (Table 4), but
the importance of monocyte recovery has not been as
well described in the literature. Monocytopenia has
previously been associated with the development of
invasive fungal infectionsbetween40and100days post-
allogeneic HSCT, although it did not retain indepen-
dence in a multivariate model [17]. However, severe
monocytopenia\0.1  109 cells/L is also associated
with reduced survival after diagnosis of an invasive fun-
gal infection postallogeneic HSCT [18]. Prospective
confirmation of our finding of achievement of a normal
monocyte count as indicative of improvedglobal immu-
nologic reconstitution and survival postallogeneic
HSCT will be required.
Because our findings are derived solely from the
complete blood cell count used in routine clinical
practice, our analysis is limited by our inability to
determine phenotypic and functional changes within
the monocyte and lymphocyte populations that may
be responsible for this survival impact. The specific cel-
lular phenotypes, including lymphocyte and monocyte
subsets and their associated cytokine/growth factor
networks, which are important for survival postalloge-
neicHSCT,will be the subject of a prospective study at
our institution. For example, HLA-DRlow/2 mono-
cytes have suppressor activity and can polarize T cell
differentiation toward regulatory T cell development
[13]. Additionally, CD11b1CD1151Gr11monocytes
have been shown to induce tolerance, promote allo-
graft survival, and support regulatoryT cell production
in the setting of cardiac transplantation [19]. The nat-
ural hypothesis that can be extended relative to alloge-
neic HSCT from these studies is that therapies
supportive of tolerogenicmyeloid cellsmay be comple-
mentary to therapies aimed at control of activated T
cells in avoidance of GVHD, the major contributor
to treatment-related mortality. Indeed, activation-dependent T cell apoptosis has been observed in the
presence of peripheral blood stem cell graftmonocytes.
This finding suggests a potential role for monocytes in
initial peripheral tolerance postallogeneic HSCT [20]
and raises the possibility of graft engineering to facili-
tate engraftment and avoid GVHD.
Successful allogeneic HSCT requires initial toler-
ance induction for successful engraftment and avoid-
ance of GVHD within the first few weeks, followed
by rapid immunologic reconstitution as the graft-
versus-leukemia (GVL) reaction evolves over the ensu-
ing months. The initial goal of allogeneic HSCT is
quite different from that of autologous HSCT, where,
in contrast to our findings, early monocyte recovery
can portend a risk of cancer relapse in the setting of
autologous HSCT for lymphoma [21]. Because graft
rejection and GVHD are not risks typically associated
with autologous transplantation, immunologic toler-
ance is not required and, in fact, could be deleterious
to any potential autologous GVL effect. This key dif-
ference between the biology and goals of autologous
versus allogeneic HSCT could account for discrepant
findings with respect to monocyte recovery observed
in the 2 different modalities. Therefore, unlike the
near-universal applicability of lymphocyte recovery
as a surrogate of successful cancer immunotherapy,
the prognostic value of rapidly achieving a normal
monocyte count may be specific to allogeneic HSCT.
Whether stimulation of a suppressive myeloid-
driven cellular network to facilitate initial engraftment
and set the stage for IR would result in an increased
risk of cancer relapse postallogeneic HSCT is not
known. Tolerance is known to be a double-edged
sword in allogeneic HSCT. The immune-mediated
eradication of leukemia relies on the absence of toler-
ance, and at present, real-time individualization of
immunity to drive either tolerance or GVL is achieved
by adjusting levels of immunosuppressants and corti-
costeroids that predominantly affect T lymphocytes.
Autografts [22] and syngeneic [23] transplants for
leukemia are much better tolerated, both in the phys-
iologic and immunologic sense, but are characterized
by a significantly less potent GVL effect, translating
into a high risk of relapse of the underlying malignan-
cies with these modalities. Newmethods of supporting
engraftment and avoidance of GVHD that affect
cellular compartments other than T cells may help
improve upon the safety and efficacy of allogeneic
HSCT, themodality with themost potent GVL effect.
In current practice, achieving the appropriate
balance between tolerance and immune activation
with the use of T cell–directed immunosuppressive
agents postallogeneic HSCT is an empiric process and
guided heavily by intuition and experience in clinical
transplantation, where competing risks are evaluated
at each posttransplantation visit within the first 100
days and beyond [24]. Despite many advances in
Table 4. Prior Studies Describing ALC Recovery Postmyeloablative, T Cell–Replete Allogeneic HSCT
Study Graft Type Conditioning Regimens GVHD Prophylaxis Diseases Principal Findings
Pavletic et al. (1998) [1] T cell–replete
Allo PBSCT (N 5 41)
Allo BMT + G-CSF (N 5 23)
Allo BMT 2 G-CSF (N 5 29)
MA (all)
(Cy/VP16/TBI or Bu/Cy
if prior radiation)
CSA + MTX AML (N 5 26)
ALL (N 5 6)
CML (N 5 33)
CLL (N 5 3)
MDS (N 5 9)
HD (N 5 1)
NHL (N 5 7)
MM (N 5 8)
Median time to ALC $500/mL was 17 days (allo PBSCT), 41 days
(allo BMT +G), and 49 days (allo BMT-G).
In allo PBSCT, median numbers of CD3+/CD8+ and CD56+ cells
within normal limits by day +28.
ALC $500  106/L by day 17 associated with improved survival
for allo PBSCT but not for allo BMT.
Kumar et al. (2001) [2] T cell–replete allo BMT
(PBSCTexcluded)
MA (all)
Cy/TBI
Bu/Cy
VP16/TBI
CSA-based (N 5 68)
Other (N 5 19)
AML (N 5 87) Improved relapse-free and overall survival if ALC $150  106/L
by day +30.
Kumar et al. (2003) [3] T cell–replete allo BMT
(PBSCTexcluded)
MA (all)
Cy/TBI
VP16/TBI
CSA-based (N 5 35)
Other (N 5 8)
ALL (N 5 43) Improved relapse-free survival and OS if ALC $175  106/L by
day +21.
Kim et al. (2006) [4] T cell–replete
PBSCT (N 5 47)
BMT (N 5 22)
MA
Bu/Cy (N 5 47)
RIC
Fludarabine-based
(N 5 22)
CSA-based (N 5 63)
Tacrolimus-based (N 5 4)
AML (N 5 42)
ALL (N 5 5)
CML (N 5 15)
NHL (N 5 5)
MDS (N 5 2)
Improved OS, NRM, and opportunistic infections if CD4+ helper
T cells $200  106/L by 3 months post-HSCT.
No difference in relapse risk with rapid CD4+ recovery.
Heining et al. (2007) [5] T cell–replete
PBSCT (N 5 81)
BMT (N 5 67)
MA
(N 5 91)
Bu/CY
VP16/Cy/TBI
RIC
Fludarabine-based (N 5 47)
CSA-based (all)
ATG (N 5 78)
AML (N 5 47)
ALL (N 5 17)
MPN (N 5 52)
MDS (N 5 10)
NHL/MM (N 5 20)
SAA (N 5 2)
Counts were log-transformed for statistical analysis.
Prolonged lymphopenia was encountered with MUD and use of ATG as
GVHD prophylaxis.
Conditioning regimen, age, incidence/extent of GVHD did not
affect lymphocyte recovery.
Le Blanc et al. (2009) [6] T cell–replete
(N 5 102)
MA (all)
Cy/TBI
Bu/Cy
CSA-based (N 5 97) AML (N 5 54)
CML (N 5 38)
MDS (N 5 10)
ALC <200  106/L by day +30 demonstrated worse TRM and RFS.
Matthews et al. (2010) [7] T cell–replete
PBSCT (N 5 25)
RIC (all)
Fludarabine/busulfan/alemtuzumab
AML (N 5 10)
MDS (N 5 11)
MPN (N 5 3)
CML (N 5 1)
No relationship between rapid lymphocyte recovery and relapse.
Buhlmann et al. (2010) [8] T cell–replete (N 5 345)
PBSCT (N 5 321)
BMT (N 5 20)
Cord (N 5 4)
MA (N 5 256)
RIC (N 5 89)
CSA ± MTX (N 5 240)
CSA + MMF (N 5 105)
ALL (N 5 54)
AML (N 5 114)
NHL (N 5 72)
MDS (N 5 43)
MPN (N 5 35)
MM (N 5 27)
NK >150  106/L and CD4+ >200 cells  106/L protected from TRM.
NK >150  106/L at 12 months protected from relapse.
Burke et al. (2011) [9] Umbilical cord blood
stem cells
MA (N 5 147)
RIC (N 5 213)
CSA + MMF ALL (N 5 75)
AML (N 5 136)
CML (N 5 8)
MDS (N 5 22)
MPN (N 5 9)
LPD (N 5 65)
Other (N 5 7)
ALC >200  106/L by day 20 for MA and by day 42 for RIC is
associated with superior OS and PFS.
ALC indicates absolute leukocyte count; ATG, antithymocyte globulin; BMT, bone marrow transplantation; Bu, busulfan; CLL, chronic lymphocytic leukemia; CSA, cyclosporine; CSF, cerebral spinal fluid; Cy, cyclo-
phosphamide; G-CSF, granulocyte-colony stimulating factor; HD, Hodgkin’s disease; LPD, lymphoproliferative disease; MA, myeloablative; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophe-
nolate mofetil; MPN, myeloproliferative neoplasm; MTX, methotrexate; MUD, matched unrelated donor; NHL, non-Hodgkin leukemia; NK, natural killer; PBSCT, peripheral blood stem cell transplantation; PFS,
progression-free survival; RIC, reduced-intensity conditioning; SAA, severe aplastic anemia; TBI, total body irradiation; TRM, treatment-related mortality.
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Biol Blood Marrow Transplant 18:600-607, 2012 607ALC and AMC Postallogeneic HSCTsupportive care of the transplant recipient [25], the pro-
cess of immune reconstitution remains slow and incom-
plete because of toxicities of the conditioning therapy,
impaired T cell, especially naive T cell, survival [26-
28], immunosuppressive medications [29], GVHD
[30], and even mature allograft T lymphocytes [31].
Here, we show that monocyte recovery may be as im-
portant as, and supportive to, lymphocyte recovery
postallogeneic HSCT, and may therefore represent an
additional immune network to therapeutically target.ACKNOWLEDGMENTS
The authors extend their gratitude to the patients
and their families who have undergone HSCT at
Mayo Clinic for whom we strive to improve outcomes.
Financial disclosure: The authors declare no com-
peting financial interests.REFERENCES
1. Pavletic ZS, Joshi SS, Pirruccello SJ, et al. Lymphocyte reconsti-
tution after allogeneic blood stem cell transplantation for hema-
tologic malignancies. Bone Marrow Transplant. 1998;21:33-41.
2. Kumar S, Chen MG, Gastineau DA, et al. Effect of slow
lymphocyte recovery and type of graft-versus-host disease
prophylaxis on relapse after allogeneic bone marrow transplan-
tation for acute myelogenous leukemia. BoneMarrow Transplant.
2001;28:951-956.
3. KumarS,ChenMG,GastineauDA, et al.Lymphocyte recovery af-
ter allogeneic bone marrow transplantation predicts risk of relapse
in acute lymphoblastic leukemia. Leukemia. 2003;17:1865-1870.
4. Kim DH, Sohn SK, Won DI, Lee NY, Suh JS, Lee KB. Rapid
helper T-cell recovery above 200 10 6/l at 3 months correlates
to successful transplant outcomes after allogeneic stem cell
transplantation. Bone Marrow Transplant. 2006;37:1119-1128.
5. Heining C, Spyridonidis A, Bernhardt E, et al. Lymphocyte
reconstitution following allogeneic hematopoietic stem cell
transplantation: a retrospective study including 148 patients.
Bone Marrow Transplant. 2007;39:613-622.
6. Le Blanc K, Barrett AJ, Schaffer M, et al. Lymphocyte recovery
is a major determinant of outcome after matched unrelated mye-
loablative transplantation for myelogenous malignancies. Biol
Blood Marrow Transplant. 2009;15:1108-1115.
7. Matthews K, Lim Z, Pearce L, et al. Rapid recovery of lympho-
cyte subsets is not associated with protection from relapse of
myelodysplastic syndromes and acute myeloid leukaemia after
haematopoietic stem cell transplantation using a reduced
intensity conditioning regimen and alemtuzumab. Br J Haema-
tol. 2010;149:879-889.
8. Buhlmann L, Buser AS, Cantoni N, et al. Lymphocyte subset
recovery and outcome after T-cell replete allogeneic hematopoi-
etic SCT. Bone Marrow Transplant. 2010 Nov 29 [Epub ahead of
print].
9. Burke MJ, Vogel RI, Janardan SK, et al. Early Lymphocyte re-
covery and outcomes after umbilical cord blood transplantation
(UCBT) for hematologic malignancies. Biol BloodMarrow Trans-
plant. 2011;17:831-840.
10. Barrett AJ, Savani BN. Does chemotherapy modify the immune
surveillance of hematological malignancies? Leukemia. 2009;23:
53-58.
11. Biswas SK, Mantovani A. Macrophage plasticity and interaction
with lymphocyte subsets: cancer as a paradigm. Nat Immunol.
2010;11:889-896.
12. Morecki S, Gelfand Y, Yacovlev E, Eizik O, Shabat Y, Slavin S.
CpG-inducedmyeloidCD11b1Gr-11 cells efficiently suppressT cell-mediated immunoreactivity and graft-versus-host disease
in a murine model of allogeneic cell therapy. Biol Blood Marrow
Transplant. 2008;14:973-984.
13. HoechstB,Gamrekelashvili J,MannsMP,GretenTF,KorangyF.
Plasticity of humanTh17 cells and iTregs is orchestrated by differ-
ent subsets of myeloid cells. Blood. 2011;117:6532-6541.
14. Cox CJ, HabermannTM, Payne BA, KleeGG, Pierre RV. Eval-
uation of the Coulter Counter model S-Plus IV. Am J Clin
Pathol. 1985;84:297-306.
15. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of
graft-versus-host disease in human recipients of marrow from
HL-A-matched siblingdonors.Transplantation. 1974;18:295-304.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete
observations. J Am Stat Assoc. 1958;53:457-481.
17. Garcia-Vidal C, Upton A, KirbyKA,Marr KA. Epidemiology of
invasive mold infections in allogeneic stem cell transplant recip-
ients: biological risk factors for infection according to time after
transplantation. Clin Infect Dis. 2008;47:1041-1050.
18. Parody R, Martino R, Sanchez F, Subira M, Hidalgo A, Sierra J.
Predicting survival in adults with invasive aspergillosis during
therapy for hematological malignancies or after hematopoietic
stem cell transplantation: single-center analysis and validation
of the Seattle, French, and Strasbourg prognostic indexes. Am
J Hematol. 2009;84:571-578.
19. Garcia MR, Ledgerwood L, Yang Y, et al. Monocytic suppres-
sive cells mediate cardiovascular transplantation tolerance in
mice. J Clin Invest. 2010;120:2486-2496.
20. InoK, Ageitos AG, SinghRK,Talmadge JE. Activation-induced
T cell apoptosis by monocytes from stem cell products. Int
Immunopharmacol. 2001;1:1307-1319.
21. Porrata LF, Inwards DJ, Ansell SM, et al. Day 15 peripheral
blood lymphocyte/monocyte ratio post-autologous periph-
eral hematopoietic stem cell transplantation and survival in
diffuse large B-cell lymphoma. J Clin Oncol. 2011;29(Suppl):
2011. abstr 8018.
22. Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoi-
etic stem cell transplantation as part of postremission therapy
improves survival for adult patients with high-risk acute lympho-
blastic leukemia: a metaanalysis. Cancer. 2006;106:2657-2663.
23. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-
leukemia reactions after bone marrow transplantation. Blood.
1990;75:555-562.
24. Pidala J, Lee SJ, QuinnG, JimH,Kim J, Anasetti C. Variation in
management of immune suppression after allogeneic hemato-
poietic cell transplantation. Biol Blood Marrow Transplant. 2011.
25. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality
after allogeneic hematopoietic-cell transplantation. N Engl J
Med. 2010;363:2091-2101.
26. Lin MT, Tseng LH, Frangoul H, et al. Increased apoptosis of
peripheral blood T cells following allogeneic hematopoietic
cell transplantation. Blood. 2000;95:3832-3839.
27. Poulin JF, Sylvestre M, Champagne P, et al. Evidence for
adequate thymic function but impaired naive T-cell survival fol-
lowing allogeneic hematopoietic stem cell transplantation in the
absence of chronic graft-versus-host disease. Blood. 2003;102:
4600-4607.
28. Matsuoka K, Kim HT, McDonough S, et al. Altered regulatory
T cell homeostasis in patients with CD41 lymphopenia
following allogeneic hematopoietic stem cell transplantation. J
Clin Invest. 2010;120:1479-1493.
29. Coenen JJ, Koenen HJ, van Rijssen E, et al. Rapamycin, not
cyclosporine, permits thymic generation and peripheral preser-
vation of CD41 CD251 FoxP31 T cells. Bone Marrow Trans-
plant. 2007;39:537-545.
30. Lee KH,Choi SJ, Lee JH, et al. Prognostic factors identifiable at
the time of onset of acute graft-versus-host disease after alloge-
neic hematopoietic cell transplantation. Haematologica. 2005;90:
939-948.
31. Muller AM,Linderman JA, FlorekM,MiklosD, Shizuru JA. Allo-
geneicTcells impair engraftment andhematopoiesis after stemcell
transplantation. Proc Natl Acad Sci USA. 2010;107:14721-14726.
